Bioventus Inc. (NASDAQ: BVS) reported Q4 EPS of ($0.06), $0.11 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $125.8 million versus the consensus estimate of $132.59 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.